MUHC Vaccine Study Centre

The MUHC Vaccine Study Centre (VSC) conducts vaccine and epidemiological research. Located in Pierrefonds, Quebec, the VSC has conducted over 200 studies with over 8,000 participants enrolled to date.

Want to make a difference? Call 514-624-7855 or text 514-239-7886.

About the MUHC Vaccine Study Centre

Founded in 1991, the MUHC Vaccine Study Centre (VSC) is affiliated with the McGill University Health Centre (MUHC) and the Research Institute of the MUHC (RI-MUHC). The experienced personnel at the VSC conduct vaccine and epidemiological research in collaboration with participants and sponsors. The VSC staff are physicians, nurses and highly trained research personnel, experienced in clinical research and meticulous in their work. They provide a caring, respectful and bilingual environment for study participants.

Our Team

Leadership
Title
Brian Ward, MD
Co-director
Jesse Papenburg, MD, M.Sc.
Co-director
Deirdre McCormack, B.Sc.(N) RN
Clinical research manager
Investigators
Affiliation
Michael Libman, MD
McGill University Health Centre
Brian Ward, MD
McGill University Health Centre
Jesse Papenburg, MD, M.Sc.
Montreal Children’s Hospital (MUHC)
Earl Rubin, MD
Montreal Children’s Hospital (MUHC)
Inés Colmegna, MD
McGill University Health Centre
Team members
Title
Monica Makarewicz, RN
Nurse coordinator
Janice Couture, RN
Nurse coordinator
Giuliana Alfonso, RN
Nurse coordinator
Patricia Brown, RN
Nurse coordinator
Jill Gale, BSc(N), M.Sc.(N), RN
Nurse coordinator
Liubov Zolotareva, B.Sc.(N), M.Sc.(N), RN
Nurse coordinator
Sandra Safulko, B.Sc.(N), RN
Research nurse
Carina Mazloumian, B.Sc.(N), RN
Research nurse
Sylvie Nicholson, RN
Research nurse
Cathy Clarke
Research assistant
Alice Weir
Research assistant
Allison Couture, B.Ed.
Research assistant
Joanne Richardson
Research assistant
Impact team
Title
Annick Audet, B.Sc.(N), RN
IMPACT Nurse Monitor liaison
Diane Delli Colli, B.Sc.(N), RN
Nurse monitor
Emily Shallhorn, B.Sc.(N), MPH
Nurse monitor back-up

Ongoing Clinical Studies

ADULT STUDIES

Study Name
Study Details
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
Sponsor: Janssen
Phase: 3
Target population: Adults 60 years and older with a history of UTI
Status: Recruiting
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 18 to 40 Years of Age
Sponsor: Moderna
Phase: 3
Target population: Women aged 18 to 40 years
Status: Recruiting
A Lyme disease vaccine (VLA15) for the prevention of Lyme disease caused by Borrelia species in individuals
Sponsor: Pfizer
Phase: 3
Target population: Healthy adults ≥ 18 years of age
Status: Not yet recruiting
COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD)
Sponsor: CIHR
Phase: 2/3
Target population: Adults with a systemic autoimmune rheumatic disease
Status: Recruiting
Reinfection in COVID-19 Estimation of Risk: extension
Sponsor: CIHR
Health Care Workers who have had COVID-19
Status: Closed to recruitment. Long-term follow-up.

PEDIATRIC STUDIES

Study Name
Study Details
Efficacy and Safety of MK-1654 in Infants (MK-1654-004)
Sponsor: Merck
Phase: 2/3
Target population: Infants
Status: Recruiting
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
Sponsor: Moderna
Phase: 3
Target population: Healthy children aged 6 months to < 12 years
Status: Closed to recruitment. Long-term follow-up.

Interested in more information about our studies? Please contact us.

Completed Studies

Pfizer - 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

Medicago - Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

RI-MUHC - COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases (COVIAAD)

MedImmune – A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

Merck - A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

Contact the MUHC Vaccine Study Centre

For more information about the MUHC Vaccine Study Centre and to learn more about participating in studies at the VSC:

Phone: 514-624-7855

Text: 514-239-7886

Email: coordinators.vsc@muhc.mcgill.ca

Visit: 14770 Pierrefonds Blvd., unit 204, Pierrefonds, Quebec H9H 4Y6

Useful Links

The MUHC Vaccine Study Centre is proud to collaborate with other vaccine research centres and networks across Canada.